Although PSMA ligand PET/CT is generally considered superior to fluorine-18 fluorodeoxyglucose ([18F]FDG) PET/CT for detecting PCa lesions (7, 8), evidence from some studies suggests that [18F]FDG PET/CT may have utility or even demonstrates higher diagnostic sensitivity in patients with poorly differentiated adenocarcinoma or neuroendocrine differentiation compared to those with well-differentiated adenocarcinoma (9–11). The gene discussed is FOLH1; the disease is adenocarcinoma.